Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for most adults with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Since HCT using conventional myeloablative conditioning (MAC) can be associated with higher toxicity and mortality rates, reduced intensity conditioning (RIC) regimens have been increasingly used in the past two decades for HCT in older and less fit patients with AML or MDS.1,2 A recent prospective randomized Blood and Marrow Transplant Clinical Trials Network (BMT CTN)  0901 trial demonstrated significantly improved disease-free survival (DFS) benefit with use of MAC compared with RIC for HCT in patients (age 18-65 years) with AML and MDS.

Source: Biology of Blood and Marrow Transplantation - September 29, 2020 Category: Hematology Authors: Nelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, Claudio Brunstein, Hailin Wang, Erica D. Warlick, Sergio Giralt, Taiga Nishihori, Rodrigo Martino, Jakob Passweg, Ajoy Dias, Edward Copelan, Gregory Hale, Robert Peter Gale, Melhem Solh, Mohamed A. Kharfan-D Source Type: research